A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)

Disease Sites:

Head/Neck

Staging:

Phase III

Age Group:

Adults

Therapies:

Mol. targeted/Immunotherapy/Biologics

Drugs:

Volrustomig (MEDI5752)

Principal Investigator(s):

Choe, Jennifer

Scope:

International

Participating Institutions:

Vanderbilt University

Open Date:

06-11-2025

Trial Type:

Treatment

Protocol ID:

VICC-DTHAN24071

National Clinical Trial ID:

NCT06129864

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available